Last reviewed · How we verify
Azubromaron (BENZBROMARONE)
Benzbromarone, also known as Azubromaron, is a small molecule drug that targets the Cytochrome P450 2C9 enzyme. It is classified as a benzbromarone and is used to treat gout and hyperuricemia. The commercial status of benzbromarone is not specified, but it is likely to be off-patent given its age. As a result, generic manufacturers may be available. Key safety considerations are not well-documented.
At a glance
| Generic name | BENZBROMARONE |
|---|---|
| Drug class | benzbromarone |
| Target | Cytochrome P450 2C9 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Gout
- Hyperuricemia
Common side effects
Key clinical trials
- Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets (PHASE4)
- Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients (PHASE2)
- Normalizing Antibody Detection in First-void Urine
- SGLT2 Inhibition: Uric Acid Excretion Study (PHASE4)
- The Influence of Urate-lowering Therapy on Sperm Quality of Male Gouty Patients：A Prospective Cohort Study
- Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction (PHASE4)
- Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia (PHASE2)
- Compare the Renal Protective Effects of Febuxostat and Benzbromarone (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azubromaron CI brief — competitive landscape report
- Azubromaron updates RSS · CI watch RSS